These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19145089)

  • 1. The ethnic profile of triple-negative breast cancer.
    Cleator SJ; Palmieri C; Coombes CR
    Onkologie; 2008 Nov; 31(11):580-2. PubMed ID: 19145089
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinicopathologic and prognostic characteristics of triple-negative breast cancer.
    Tian XS; Cong MH; Zhou WH; Zhu J; Chen YZ; Liu Q
    Onkologie; 2008 Nov; 31(11):610-4. PubMed ID: 19145094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
    Su Y; Zheng Y; Zheng W; Gu K; Chen Z; Li G; Cai Q; Lu W; Shu XO
    BMC Cancer; 2011 Jul; 11():292. PubMed ID: 21749714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are triple-negative and basal-like breast cancer synonymous?
    Rakha E; Ellis I; Reis-Filho J
    Clin Cancer Res; 2008 Jan; 14(2):618; author reply 618-9. PubMed ID: 18223240
    [No Abstract]   [Full Text] [Related]  

  • 5. Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience.
    Aksoy S; Dizdar O; Harputluoglu H; Altundag K
    Ann Oncol; 2007 Nov; 18(11):1904-6. PubMed ID: 17993632
    [No Abstract]   [Full Text] [Related]  

  • 6. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
    Abubakar M; Sung H; Bcr D; Guida J; Tang TS; Pfeiffer RM; Yang XR
    Breast Cancer Res; 2018 Sep; 20(1):114. PubMed ID: 30227867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone status and demographics in early onset breast cancer patients.
    Friend KE; Perry RR; Collins JN; Britt RC; Feliberti EC
    Am Surg; 2012 Jul; 78(7):819-21. PubMed ID: 22748546
    [No Abstract]   [Full Text] [Related]  

  • 8. From the guest editor: Triple-negative breast cancer.
    Hudis CA
    Cancer J; 2010; 16(1):10-1. PubMed ID: 20164684
    [No Abstract]   [Full Text] [Related]  

  • 9. Triple-negative breast cancer.
    Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
    [No Abstract]   [Full Text] [Related]  

  • 10. New approaches for triple-negative breast cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999
    [No Abstract]   [Full Text] [Related]  

  • 11. [Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases].
    Guan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):196-9. PubMed ID: 18756935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer and brain metastases.
    Sait B; Cinar E; Altundag K
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):84. PubMed ID: 19751969
    [No Abstract]   [Full Text] [Related]  

  • 13. Triple-negative breast cancer: MRI features in 29 patients.
    Chen JH; Agrawal G; Feig B; Baek HM; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
    Ann Oncol; 2007 Dec; 18(12):2042-3. PubMed ID: 18029970
    [No Abstract]   [Full Text] [Related]  

  • 14. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
    Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
    J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.
    Piccart MJ
    Ann Oncol; 2012 Aug; 23 Suppl 6():vi5-6. PubMed ID: 23012303
    [No Abstract]   [Full Text] [Related]  

  • 16. CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark.
    Narod SA; Dent RA; Foulkes WD
    Clin Cancer Res; 2015 Sep; 21(17):3813-4. PubMed ID: 26330504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different subtypes of metaplastic breast cancer might have different sensitivity to neoadjuvant chemotherapy.
    Altundag K
    J BUON; 2019; 24(5):2205. PubMed ID: 31786895
    [No Abstract]   [Full Text] [Related]  

  • 18. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
    Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
    J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
    [No Abstract]   [Full Text] [Related]  

  • 19. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
    Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy for triple negative breast cancer.
    De Giorgi U; Rosti G; Frassineti L; Kopf B; Giovannini N; Zumaglini F; Marangolo M
    Ann Oncol; 2007 Jan; 18(1):202-203. PubMed ID: 16971660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.